Clinical Trials Directory

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGEŽ) therapy, and to follow all subjects for survival.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • biological : sipuleucel-T

Phase: N/A


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- subjects must be at least 18 years of age - subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ? 6 months prior to enrollment - subjects must understand and sign an informed consent form

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
Not Recruiting

Footer Links: